Evidence map›Paper›PMID 16479524›Full record

ArticleThe Journal of infectious diseases2006

Pulmonary V beta 4+ T cells from Histoplasma capsulatum-infected mice respond to a homologue of Sec31 that confers a protective response.

Mark R Scheckelhoff, George S Deepe

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Comparative Genomics ofJournal of fungi (Basel, Switzerland) · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mark R ScheckelhoffDivision of Infectious Diseases, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0560, USA.
George S Deepe

Funding

PROTECTIVE ANTIGENS FROM HISTOPLASMA CAPSULATUMR01AI034361 · NIAID · UNIVERSITY OF CINCINNATI · PI DEEPE, GEORGE S. · 1993 to 2007
$2.5M
T CELL RECEPTOR USAGE IN PULMONARY HISTOPLASMOSISR37AI042747 · NIAID · UNIVERSITY OF CINCINNATI · PI DEEPE, GEORGE S. · 1997 to 2006
$2.2M
NIAID NIH HHS AI-34361NIAID NIH HHS AI-43747NIAID NIH HHS R01 AI034361NIAID NIH HHS R37 AI042747
6 · The paper itself

Abstract

The population of V beta 4+ T cells expands in the lungs of C57BL/6 mice infected with Histoplasma capsulatum, and the elimination of these cells impairs protective immunity. To determine the antigen or antigens that trigger their proliferation, V beta 4+ T cell hybridomas were generated from the lungs and spleens of infected mice. We mapped the antigenic determinants by T cell Western blot. Pulmonary and splenic T cells recognized 3 regions comprising <25, 55-70, and 125-140 kDa. The majority of hybridomas from lungs, but not from spleens, responded to the high molecular mass region. A protein from that area was identified, by amino acid sequencing, as a homologue of Sec31 from Saccharomyces cerevisiae. Vaccination with recombinant Sec31 reduced fungal burden and improved survival in mice, and its efficacy was critically dependent on the presence of V beta 4+ T cells. Thus, a homologue of Sec31 is a trigger of the expansion of the V beta 4+ T cell population and is important to the generation of protective immunity.

Indexed as

AnimalsCarrier ProteinsHistoplasmaHistoplasmosisMiceMice, Inbred C57BLPhosphoproteinsReceptors, Antigen, T-Cell, alpha-betaSaccharomyces cerevisiae ProteinsVesicular Transport ProteinsCarrier ProteinsPhosphoproteinsReceptors, Antigen, T-Cell, alpha-betaSaccharomyces cerevisiae ProteinsSEC31 protein, S cerevisiaeVesicular Transport Proteins

Identifiers

PMID16479524
PMCPMC1393281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.